Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Lung. 2016 Mar 17;194(3):401–408. doi: 10.1007/s00408-016-9867-2

Fig. 5.

Fig. 5

PKI 14-22 (PKA inhibitor) completely reverses terbutaline-induced decrease in fractional 3H-GABA release in cultured human airway epithelial (BEAS-2B) cells. Terbutaline (100 μM) treatment decreased fractional 3H-GABA release, and this decrease was completely reversed by co-treatment with the PKA inhibitor PKI 14-22 (1 μM). n = 4, **p < 0.01, *p < 0.05 ANOVA with repeated measures

HHS Vulnerability Disclosure